Digital Health Innovation and Informatics
PV QA 2 - Poster Viewing Q&A 2
MO_17_2595 - App-based PRO monitoring in geriatric patients undergoing radiation therapy - an initial analysis of the prospective TeleGraPH trial.
Monday, October 22
10:45 AM - 12:15 PM
Location: Innovation Hub, Exhibit Hall 3
App-based PRO monitoring in geriatric patients undergoing radiation therapy – an initial analysis of the prospective TeleGraPH trial.
F. A. Giordano1, V. Siefert2, G. Welzel3, M. Blessing3, C. Neumaier3, L. Jahnke1, J. Hesser4, and F. Wenz1; 1Department of Radiation Oncology, Universitaetsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany, 2Department of Radiation Oncology, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Germany, Mannheim, Germany, 3Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany, 4Experimental Radiation Oncology, Medical Faculty Mannheim, University of Heidelberg, Germany, Mannheim, Germany
Purpose/Objective(s): Recent randomized trials indicated that electronic assessment of PRO may significantly improve overall survival of patients with metastatic cancers. Although this is a major advancement in palliative cancer care, there were concerns that only young(er) patients with access to mobile devices may benefit from such digital cancer care. We therefore initiated TeleGraPH (Telemonitoring of Geriatric Cancer Patients Using Handheld Devices), a prospective trial assessing the compliance of elderly cancer patients to use handheld devices for symptom and QoL reporting during/after radiotherapy.
Materials/Methods: TeleGraPH is a prospective feasibility study on an App-based symptom and QoL follow-up (CareOnlineTM, humediQ GmbH, Grünwald) in geriatric cancer patients. Inclusion Criteria were age>60, KPS ≥ 70 and a histologically confirmed primary tumor. Primary outcome is compliance (defined as number of questionnaires answered per time frame, time frame: 0-3 months after enrollment), secondary outcome is HRQL (EORTC-QLQ30). Additional items were the subjective perception of the health status (SPHS) as well as the body weight. We here report data from an interim analysis on compliance and an (exploratory) comparative analysis between curative and palliative patients. The trial is registered with ClinicalTrials.gov, number NCT03196050.
Results: A total of 48 patients were included in this interim analysis. 18 patients (38%) were excluded due to personal or study- related issues after enrollment. The median follow-up was 3.5 months (0.4-13.9 months). The most frequent primary disease was prostate cancer (37%), followed by breast cancer (10%), small-cell-lung-cancer (10%) and glioblastoma (10%). The mean compliance after 15 days was 73% decreasing to 55% after 90 days. There were no significant differences with regard to compliance between the curative and palliative groups. However, the palliative group showed a decrease in weight and little to no improvements in SPHS whereas the weight was stable and the SPHS improved in the curative group.
Conclusion: This trial established important benchmarks for future digital care of geriatric cancer patients. Roughly 60% of all geriatric cancer patients participate in App-based follow-up during/after radiotherapy, ¾ of those respond within the first 2 weeks and ½ will use this follow-up technology for more than three months. Funded by the Federal Ministry of Economic Affairs of Germany, the H.W. & J. Hector Foundation and humediQ GmbH.
Author Disclosure: F.A. Giordano: None. V. Siefert: None. G. Welzel: None. M. Blessing: None. C. Neumaier: Independent Contractor; carl zeiss meditec. Honoraria; carl zeiss meditec. F. Wenz: Research Grant; Elekta AB, Carl Zeiss Meditec AG. Honoraria; Roche Pharma AG. Consultant; Celgene.